JP2021528399A5 - - Google Patents
Info
- Publication number
- JP2021528399A5 JP2021528399A5 JP2020570143A JP2020570143A JP2021528399A5 JP 2021528399 A5 JP2021528399 A5 JP 2021528399A5 JP 2020570143 A JP2020570143 A JP 2020570143A JP 2020570143 A JP2020570143 A JP 2020570143A JP 2021528399 A5 JP2021528399 A5 JP 2021528399A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- formulation
- binds
- formulation according
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688476P | 2018-06-22 | 2018-06-22 | |
| US62/688,476 | 2018-06-22 | ||
| US201962855205P | 2019-05-31 | 2019-05-31 | |
| US62/855,205 | 2019-05-31 | ||
| PCT/US2019/038600 WO2019246595A1 (en) | 2018-06-22 | 2019-06-21 | Dosing regimens for targeted tgf-b inhibition for use in treating biliary tract cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021528399A JP2021528399A (ja) | 2021-10-21 |
| JP2021528399A5 true JP2021528399A5 (cg-RX-API-DMAC7.html) | 2022-09-12 |
Family
ID=68982740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570143A Pending JP2021528399A (ja) | 2018-06-22 | 2019-06-21 | 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画 |
Country Status (14)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202304979A (zh) * | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2023045141A1 (zh) * | 2021-09-26 | 2023-03-30 | 上海迈泰君奥生物技术有限公司 | 一种双功能融合蛋白 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016014952A2 (pt) * | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
-
2019
- 2019-06-21 KR KR1020217001689A patent/KR20210022680A/ko not_active Withdrawn
- 2019-06-21 AU AU2019288765A patent/AU2019288765A1/en not_active Abandoned
- 2019-06-21 WO PCT/US2019/038600 patent/WO2019246595A1/en not_active Ceased
- 2019-06-21 TW TW108121691A patent/TW202019959A/zh unknown
- 2019-06-21 CA CA3103908A patent/CA3103908A1/en active Pending
- 2019-06-21 SG SG11202012688UA patent/SG11202012688UA/en unknown
- 2019-06-21 CN CN201980054914.7A patent/CN112673020A/zh active Pending
- 2019-06-21 JP JP2020570143A patent/JP2021528399A/ja active Pending
- 2019-06-21 EP EP19822318.2A patent/EP3810654A4/en not_active Withdrawn
- 2019-06-21 BR BR112020026159-9A patent/BR112020026159A2/pt not_active Application Discontinuation
- 2019-06-21 MX MX2020014166A patent/MX2020014166A/es unknown
-
2020
- 2020-12-17 US US17/125,108 patent/US20210214446A1/en not_active Abandoned
- 2020-12-21 IL IL279647A patent/IL279647A/en unknown
- 2020-12-21 CL CL2020003323A patent/CL2020003323A1/es unknown